Literature DB >> 1430393

Malignant tumors in patients with psoriasis.

J H Olsen1, H Møller, G Frentz.   

Abstract

BACKGROUND: There is strong epidemiologic evidence that psoriasis treatments may cause nonmelanoma skin cancer and possibly other types of cancer.
OBJECTIVE: This study from Denmark reports the cancer incidence in 6910 patients with psoriasis discharged from the hospital from 1977 through 1987.
METHODS: Patients were identified in the National Hospital Discharge Register and information on cases of cancer was obtained through the files of the Danish Cancer Registry; observed figures were compared with those expected on the basis of cancer incidence rates for the national population.
RESULTS: A 2.5-fold increased risk was observed for nonmelanoma skin cancer in men and women, with no preponderance of any specific histologic subtype of cancer. In addition, excesses were seen of lung cancer in men (relative risk [RR] = 1.4) and women (RR = 1.6), of cancer of the larynx and pharynx in men (RR = 2.8 and 3.9), and of colon and kidney cancer in women (RR = 1.6 and 2.3).
CONCLUSION: The effect of cigarette smoking on the risk for noncutaneous cancer could not be assessed in this study; however, antipsoriatic treatment such as ionizing radiation and oral arsenicals must be considered as a possible cause of colon cancer, which has been observed in excess in two other studies of psoriatic patients.

Entities:  

Mesh:

Year:  1992        PMID: 1430393     DOI: 10.1016/0190-9622(92)70244-a

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

1.  Smoking and psoriasis.

Authors:  H C Williams
Journal:  BMJ       Date:  1994-02-12

Review 2.  Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis. Do the known risks now outweigh the benefits?

Authors:  B Lindelöf
Journal:  Drug Saf       Date:  1999-04       Impact factor: 5.606

3.  A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohort.

Authors:  Rachael L Gross; Julie S Schwartzman-Morris; Michael Krathen; George Reed; Hong Chang; Katherine C Saunders; Mark C Fisher; Jeffrey D Greenberg; Chaim Putterman; Philip J Mease; Alice B Gottlieb; Joel M Kremer; Anna Broder
Journal:  Arthritis Rheumatol       Date:  2014-06       Impact factor: 10.995

Review 4.  National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.

Authors:  Alexa B Kimball; Dafna Gladman; Joel M Gelfand; Kenneth Gordon; Elizabeth J Horn; Neil J Korman; Gretchen Korver; Gerald G Krueger; Bruce E Strober; Mark G Lebwohl
Journal:  J Am Acad Dermatol       Date:  2008-03-04       Impact factor: 11.527

5.  Psoriasis vulgaris and familial cancer risk- a population-based study.

Authors:  Romuald Maleszka; Katarzyna Paszkowska-Szczur; Ewa Soczawa; Magdalena Boer; Monika Różewicka-Czabańska; Joanna Wiśniewska; Aneta Mirecka; Lidia Krysztoforska; Zygmunt Adamski; Jan Lubinski; Tadeusz Dębniak
Journal:  Hered Cancer Clin Pract       Date:  2013-06-28       Impact factor: 2.857

6.  Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies.

Authors:  A Blauvelt; C Paul; P van de Kerkhof; R B Warren; A B Gottlieb; R G Langley; F Brock; C Arendt; M Boehnlein; M Lebwohl; K Reich
Journal:  Br J Dermatol       Date:  2020-09-06       Impact factor: 9.302

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.